MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Novo Nordisk A-S

Cerrado

SectorSalud

69.79 0.2

Resumen

Variación precio

24h

Actual

Mínimo

69.06

Máximo

69.82

Métricas clave

By Trading Economics

Ingresos

804M

29B

Ventas

-7.6B

78B

P/B

Media del Sector

18.735

39.564

BPA

6.53

Rentabilidad por dividendo

2.34

Margen de beneficio

37.182

Empleados

77,406

EBITDA

5.9B

46B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+13.8% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.34%

2.40%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

50B

316B

Apertura anterior

69.59

Cierre anterior

69.79

Noticias sobre sentimiento de mercado

By Acuity

71%

29%

346 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Novo Nordisk A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 may 2025, 11:36 UTC

Principales Noticias

Novo Nordisk CEO to Step Down Amid Market Challenges

12 may 2025, 09:36 UTC

Principales Movimientos del Mercado

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7 may 2025, 11:29 UTC

Principales Noticias
Ganancias
Principales Movimientos del Mercado

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

9 jul 2025, 10:59 UTC

Charlas de Mercado

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Acciones populares

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

24 jun 2025, 10:26 UTC

Charlas de Mercado

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23 jun 2025, 13:09 UTC

Charlas de Mercado

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20 jun 2025, 13:31 UTC

Adquisiciones, fusiones, absorciones

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13 jun 2025, 11:39 UTC

Charlas de Mercado

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13 jun 2025, 10:04 UTC

Charlas de Mercado

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11 jun 2025, 09:45 UTC

Charlas de Mercado

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10 jun 2025, 13:38 UTC

Acciones populares

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9 jun 2025, 10:09 UTC

Charlas de Mercado

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3 jun 2025, 15:03 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 may 2025, 01:00 UTC

Principales Noticias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 may 2025, 14:08 UTC

Ganancias

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 may 2025, 07:43 UTC

Charlas de Mercado

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 may 2025, 18:35 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 may 2025, 17:34 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16 may 2025, 13:42 UTC

Acciones populares

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 may 2025, 13:27 UTC

Charlas de Mercado

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16 may 2025, 13:15 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16 may 2025, 12:17 UTC

Ganancias

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 18:45 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 may 2025, 12:07 UTC

Charlas de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 may 2025, 07:20 UTC

Charlas de Mercado

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7 may 2025, 15:13 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7 may 2025, 13:56 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 may 2025, 13:45 UTC

Ganancias

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S Esperado

Precio Objetivo

By TipRanks

13.8% repunte

Estimación a 12 meses

Media 79.25 USD  13.8%

Máximo 102 USD

Mínimo 61 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

3

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

62.63 / 69.23Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

346 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.